Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.

British journal of cancer - 14 May 2013

Cizkova M, Dujaric M-E, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga J-Y, Marty M, de Cremoux P, Spyratos F, Bieche I

Abstract excerpt

BACKGROUND: Phosphatidylinositol 3-kinase (PI3K) pathway activation has been suggested to negatively influence response to anti-HER2 therapy in breast cancer patients. The present study focused on mutations of the PIK3CA gene, encoding one of the two PI3K subunits. METHODS: PIK3CA mutations were assessed by direct sequencing in 80 HER2-positive patients treated with 1 year of trastuzumab. All patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Disease-Free Survival

Share to Docetaxel

Share to Receptor, ErbB-2

Share to Taxoids

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 23612454
DOI: 10.1038/bjc.2013.164
PMCID: PMC3658522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.PMID 23612454Read ↗

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Semantic proximity Read ↗

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.Semantic proximity Read ↗

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.Semantic proximity Read ↗

The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

PIK3CA mutation associates with improved outcome in breast cancer.Semantic proximity Read ↗

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Semantic proximity Read ↗

PI3K mutations in breast cancer: prognostic and therapeutic implicationsSemantic proximity Read ↗

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.Semantic proximity Read ↗

PIK3CA mutations in breast cancer are associated with poor outcome.Semantic proximity Read ↗

Analysis of PIK3CA Mutations with Clinicopathological Features and Prognosis in Breast cancer patients with Undergoing Neoadjuvant TherapySemantic proximity Read ↗

PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.